By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Entest Biomedical, Inc. 

San Diego  California    U.S.A.
Phone: n/a Fax:


Medical Device

Company News
Entest Biomedical, Inc.'s Subsidiary Zander Therapeutics, Inc., Reports Its Series A Compounds Suppressed The Production Of Multiple Cytokines Known To Be Involved In Inflammation With No Toxicity In Canine Studies 6/14/2017 8:32:46 AM
Entest Biomedical, Inc.'s Subsidiary EnteroMedics (ETRM) Reports On Preliminary Canine Experiments Testing New Anti-Inflammatory Drug Compounds 6/7/2017 10:07:23 AM
Entest Biomedical, Inc. Settles $841,531 Of Principal Indebtedness Through The Issuance Of Equity Securities 5/31/2017 10:48:05 AM
Entest Biomedical, Inc. Subsidiary Zander Therapeutics, Inc. Discusses Developments In Medicinal Chemistry For Veterinary Applications Of Cancer And Autoimmune Therapies Through Modulation Of Checkpoint NR2F6 5/24/2017 8:07:25 AM
Entest Biomedical, Inc.'s Chairman Discusses Its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies For Treating Cancer And Arthritis In Dogs 4/27/2017 11:55:43 AM
Entest Biomedical, Inc.'s Subsidiary, Zander Therapeutics, Inc., Initiates Ex Vivo Studies On Modulating NR2F6 In Canines 4/19/2017 8:32:03 AM
Entest Biomedical, Inc.'s Subsidiary Zander Therapeutics, Inc. Announces Appointment Of Dr. Thomas Donnelly To Serve As Senior Veterinary Advisor 3/9/2017 11:38:14 AM
Entest Biomedical, Inc.'s Zander Therapeutics, Inc. Unit Announces Publication Of Canine Cellular Immunotherapy Patent Application For Treating Cancer In Dogs 2/15/2017 6:43:37 AM
Entest Biomedical, Inc.'s Subsidiary Zander Therapeutics Makes Key Additions To Management Team As The Company Prepares To Move Forward In The $63 Billion Veterinary / Pet Market Niche 2/6/2017 9:06:32 AM
Entest Biomedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary And Future Plans For The Company Moving Into 2017 12/27/2016 9:52:03 AM